Articles by Marian (YoonJee) Chu

Asia Bio 2025

Piecing mosaic of APAC regulations key to Asia biotech growth

Sep. 10, 2025

“The comment I hear a lot from scientists … is that science has no borders,” Arif Noorani, partner at Sidley Austin LLP, said while addressing the panel audience at Asia Bio 2025 in Singapore. “I agree, but the reality is, we do have a lot of borders.”

Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal

Sep. 9, 2025

By Marian (YoonJee) Chu

No Comments

Braveheart Bio Inc. is paying $65 million up front to license Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s oral hypertrophic cardiomyopathy drug candidate called HRS-1893.

Global Bio Conference 2025

The ‘molecular revolution’ driving R&D of new cancer therapeutics

Sep. 9, 2025

By Marian (YoonJee) Chu

No Comments

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at the Global Bio Conference in Seoul, South Korea Sept. 3.

South Korea INDs: Pimedbio, Sillajen, Genosco, SK Bio, Ami

Sep. 9, 2025

By Marian (YoonJee) Chu

No Comments

Several South Korean biotech and biopharmaceutical companies completed IND submissions or won nods to start clinical trials in either the U.S. or South Korea, including SK Bioscience Co. Ltd., Genosco Inc., Pimedbio Inc., Sillajen Inc. and Ami Pharm Co. Ltd.

Asia Bio 2025

Amid U.S. uncertainties, APAC innovation looking to fill the gap

Sep. 9, 2025

By Marian (YoonJee) Chu

No Comments

Countries in the Asia Pacific (APAC) region have an opportunity, or a time-limited “gap,” to become leaders on the global biotechnology stage, panelists at the Bio Asia 2025 conference said in Singapore Sept. 9.

Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal

Sep. 5, 2025

By Marian (YoonJee) Chu

No Comments

Braveheart Bio Inc. is paying $65 million up front to license Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s oral hypertrophic cardiomyopathy drug candidate called HRS-1893.

Global Bio Conference 2025

The ‘molecular revolution’ driving R&D of new cancer therapeutics

Sep. 4, 2025

By Marian (YoonJee) Chu

No Comments

South Korea INDs: Pimedbio, Sillajen, Genosco, SK Bio, Ami

Sep. 3, 2025

By Marian (YoonJee) Chu

No Comments

K-Sure Chairman and President Jang Young-jin Ryu (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing

Korea pharma group to support exports, Korea-Japan-China trade

Sep. 2, 2025

By Marian (YoonJee) Chu

No Comments

The Korea Pharmaceutical Traders Association said Aug. 26 that it signed a strategic agreement with Korea Trade Insurance Corp. to support South Korean companies exporting biopharmaceutical materials overseas.

Fosun out-licenses immunology candidate to Sitala in $675M deal

Sep. 2, 2025

By Marian (YoonJee) Chu

No Comments

Shanghai Fosun Pharmaceutical (Group) Co. Ltd.’s subsidiary, Shanghai Fosun Pharma Industrial, signed off ex-China rights to a phase II small-molecule inhibitor, FXS-6837, to Sitala Bio Ltd. in a potential $675 million deal.

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...